



## **ONCOMETHYLOME SCIENCES RECEIVES ISO 9001:2008 CERTIFICATION**

**DURHAM, NC, and LIEGE, BELGIUM** – May 27, 2010, 10:00 CET - OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, announced today that its Belgium based clinical diagnostics service laboratory has received the important ISO 9001:2008 certification from Lloyds Register Quality Assurance Ltd.

ISO's internationally recognized standard confirms that Oncomethylome Sciences' Quality Management System consistently meets customer and regulatory requirements for research, design, assay development and clinical molecular diagnostic service testing.

"The ISO certification for our quality management system constitutes an essential validation of OncoMethylome's pharmaceutical and clinical diagnostic business activities and demonstrates our commitment to develop the highest quality products and services for our customers," said Dr. Jan Groen, President and Chief Executive Officer of OncoMethylome.

### **About OncoMethylome Sciences**

OncoMethylome Sciences SA is a leading molecular diagnostics company that commercializes and develops cancer-screening tests to assist physicians in detecting and treating cancer early. The company's tests are based on proprietary gene methylation technology invented at Johns Hopkins University and are designed to help the physician accurately detect early stages of cancer development, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome Sciences collaborates with leading cancer research centers such as Johns Hopkins, in Baltimore, MD, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough, GlaxoSmithKline Biologicals, Roche, Millipore Corporation's BioScience Division, Merck KGaA and Qiagen.

### **For more information:**

Dr. Jan Groen

CEO

+32 4.364.20.70 office

[IR@oncomethylome.com](mailto:IR@oncomethylome.com)

*This press release contains forward-looking statements and estimates with respect to the anticipated future performance of OncoMethylome and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different.*